Abstract:Background Several cell-based therapies for adjunctive treatment of acute myocardial infarction have been investigated in multiple clinical trials, but the timing of transplantation remains controversial. We conducted a meta-analysis of randomized controlled trials to investigate the effects of timing on bone marrow-derived cell (BMC) therapy in acute myocardial infarction (AMI). Methods A systematic literature search of PubMed, MEDLINE, and Cochrane Evidence-Based Medicine databases from January 2000 to June 2017 was performed on randomized controlled trials with at least a 3-month follow-up for patients with AMI undergoing emergency percutaneous coronary intervention (PCI) and receiving intracoronary BMC transfer thereafter. The defined end points were left ventricular (LV) ejection fraction, LV end-diastolic and end-systolic index. The data were analyzed to evaluate the effects of timing on BMC therapy. Results Thirty-four RCTs comprising a total of 2,307 patients were included; the results show that, compared to the control group, AMI patients who received BMC transplantation showed significantly improved cardiac function. BMC transplantation 3–7 days after PCI (+3.32%; 95% CI, 1.91 to 4.74; P < 0.00001) resulted in a significant increase of left ventricular ejection fraction (LVEF). As for the inhibitory effect on ventricular remodeling, BMC transplantation 3–7 days after PCI reduced LV end-diastolic indexes (–4.48; 95% CI, −7.98 to –0.98; P = 0.01) and LV end-systolic indexes (–6.73; 95% CI, –11.27 to –2.19; P = 0.004). However, in the groups who received BMC transplantation either within 24 hours or later than 7 days there was no significant effect on treatment outcome. In subgroup analysis, the group with LVEF ≤ 50% underwent a significant decrease in LV end-diastolic index after BMC transplantation (WMD = –3.29, 95% CI, –4.49 to –2.09; P < 0.00001); the decrease was even more remarkable in the LV end-systolic index after BMC transplantation in the group with LVEF ≤ 50% (WMD = –5.25, 95% CI, –9.30 to –1.20; P = 0.01), as well as in patients who received a dose of 10^7–10^8 cells (WMD = –12.99, 95% CI, –19.07 to –6.91; P < 0.0001). In the group with a follow-up of more than 12 months, this beneficial effect was significant and increased to a more pronounced effect of +3.58% (95% CI, 1.55 to 5.61; P = 0.0006) when compared with control. Conclusions In this meta-analysis, BMC transfer at 3 to 7 days post-AMI was superior to transfer within 24 hours or more than 7 days after AMI in improving LVEF and decreasing LV end-systolic dimensions or LV end-diastolic dimensions. It is more effective in patients with lower baseline LVEF (≤50%) and the effect can last more than 12 months.

Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: A pooled subgroup analysis of randomized controlled trials

Effects of timing on intracoronary autologous bone marrow-derived cell transplantation in acute myocardial infarction: a meta-analysis of randomized controlled trials

Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: a meta-analysis of randomised controlled trials.

P373 Systematic Review of the Safety of Intracoronary Autologous Bone Marrow Stem Cells Transfer in Patients with Acute Myocardial Infarction

Safety and Efficacy of Intracoronary Hypoxia-Preconditioned Bone Marrow Mononuclear Cell Administration for Acute Myocardial Infarction Patients: the China-Ami Randomized Controlled Trial

Timing for intracoronary administration of bone marrow mononuclear cells after acute ST-elevation myocardial infarction: a pilot study

Abstract 20556: Safety and Efficacy of Intracoronary Hypoxia-PrecondItioned Bone Marrow Mononuclear Cells Administration for Acute Myocardial Infarction Patients

Efficacy and safety of intracoronary autologous bone marrow-derived cell transplantation in patients with acute myocardial infarction: insights from randomized controlled trials with 12 or more months follow-up.

Short-Term Effect of Autologous Bone Marrow Stem Cells to Treat Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Clinical Trials.

Effect of Intracoronary Autologous Bone Marrow Stem Cells Transfer on Left Ventricular Function after Acute Myocardial Infarction

The Beneficial Effects of Intracoronary Autologous Bone Marrow Stem Cell Transfer As an Adjunct to Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials

Timing of Transplantation of Autologous Bone Marrow Derived Mesenchymal Stem Cells for Treating Myocardial Infarction

Long-term efficacy of emergent intracoronary transplantation of autologous bone marrow mononuclear cells for treatment of acute myocardial infarction

Efficacy of Emergent Transcatheter Transplantation of Stem Cells for Treatment of Acute Myocardial Infarction (Tct-Stami)

Methodological Exploration of Bone Marrow Stem Cell Therapy in Acute Myocardial Infarction – How to Achieve Greater Benefit on Cardiac Outcomes: A Systematic Review and Meta-Analysis

Efficacy of Emergent Intracoronary Transplantation of Bone Marrow Mononuclear Cells for Treatment of Acute Myocardial Infarction (TCT-STAMI)

[Observation on the Safety: Clinical Trail on Intracoronary Autologous Bone Marrow Mononuclear Cells Transplantation for Acute Myocardial Infarction].

Optimal Time for Autologous Bone Marrow Mesenchymal Stem Cells Transfer in Patients with Myocardial Infarction

[Intracoronary Transfer Autologous Bone Marrow Stem Cells Can Improve Cardiac Function in Patients with Left Ventricular Dysfunction after Myocardial Infarction].

[Long term follow-up on emergent intracoronary autologous bone marrow mononuclear cell transplantation for acute inferior-wall myocardial infarction]